Drugs / MP4CO
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01356485 | Jan → Dec 2012 | sickle cell-hemoglobin c disease syndrome | Sangart | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01925001 | Oct 2013 → Jun 2015 | sickle cell-hemoglobin c disease syndrome | Sangart | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MP4CO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01356485 ↗ |
| Modality | Protein / enzyme biologic | “chemically modified hemoglobin such as MP4CO might have the ideal properties as an oxygen therapeutic agent” NCT01356485 ↗ |
| Route | Intravenous | “administered intravenously” NCT01356485 ↗ |